SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

SPY is surging as market participants react to headlines regarding potential diplomatic negotiations to end the ongoing conflict in the Middle East, despite ongoing volatility in oil prices. The community remains deeply divided, with many debating whether the rally is a genuine recovery or a temporary relief pop driven by unverified news and algorithmic positioning.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The market is experiencing a high-volatility relief rally driven by conflicting headlines regarding potential war de-escalation in the Middle East and end-of-quarter portfolio rebalancing. While many traders are skeptical and labeling the move a bull trap, the community remains deeply divided, with bears pointing to elevated oil prices as a sign of underlying fragility while bulls are aggressively buying the dip on expectations of institutional support.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending as investors debate whether the current price represents a deep-value buying opportunity or a signal of further downside, with the community closely tracking high short interest, institutional accumulation, and technical support levels. Despite frustration over consistent downward pressure and the recent executive transition, many long-term bulls remain focused on the company's patent portfolio, expanding enterprise partnerships, and projected growth in agentic AI.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trading higher as the market weighs escalating conflict in the Middle East and the uncertainty surrounding the Strait of Hormuz against mixed signals from U.S. leadership regarding peace negotiations. The community is sharply divided, with many traders betting on further supply shocks and potential price surges, while others view current levels as an overextended rally susceptible to sudden corrections.

Spdr Dow Jones Industrial Average ETF Trust - Units of undivided interest in DIAMONDS Trust Series 1

The SPDR Dow Jones Industrial Average ETF (DIA) is experiencing heightened volatility and downward pressure as market sentiment reacts to the ongoing conflict in the Middle East and concerns over energy inflation. Community discussions are centered on the impact of shifting geopolitical news, Iranian energy infrastructure threats, and the potential for a broader economic recession, with many traders debating whether the market is reaching a capitulation point or if further declines are inevitable.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors gear up for the upcoming AAD conference in Denver, where clinical data regarding its lead skin disease drug will be presented. The community is actively discussing the drug's potential for best-in-class status in treating hidradenitis suppurativa, fueling speculation around clinical breakthroughs, M&A possibilities, and potential price movement.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The biotech sector is experiencing significant volatility and renewed investor interest, driven by a wave of high-premium M&A activity and positive data readouts for late-stage pipeline assets. While broader market uncertainty and geopolitical concerns have created a tug-of-war in price action, the community remains intensely focused on identifying potential buyout targets and monitoring institutional accumulation patterns within small-cap biotech leaders.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently facing intense selling pressure as broader crypto markets struggle under the weight of heightened geopolitical tensions and institutional outflows. While some traders are bracing for further downside, the community is deeply divided between those calling for a structural bottom and others fearing a prolonged correction fueled by macroeconomic instability.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors gear up for the upcoming release of the company's 2025 Annual Report and earnings call, which are being closely watched for signs of a turnaround. The community is actively debating the stock's potential for a squeeze, citing high short interest and a significant valuation gap compared to its underlying assets, while tracking the company's recent debt reduction efforts.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is facing intense volatility as market participants debate the company's aggressive dilution strategy for Bitcoin accumulation amidst broader macroeconomic concerns and recent quantum computing headlines. The community remains deeply polarized, with bulls highlighting the potential of Saylor's treasury model while bears increasingly warn of sustainability risks, dividend pressures, and potential downside price targets.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Elon Musk’s Neuralink is reportedly exploring the use of its brain implant device to translate thoughts into text, aiming to enable people with speech impairments to communicate.Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-19/musk-s-neuralink-plans-speech-trial-nonmedical-brain-implant">reported</a> on Friday that Neuralink plans to launch a clinical trial in the U.S. in October for this purpose. The company also hopes to have its device in a healthy person by 2030, the report added.&nbsp;“We’re currently envisioning a world where in about 3 to 4 years, there will be someone who’s otherwise healthy who’s going to get a Neuralink,” the company’s president, DJ Seo, said at the Korea Foundation for Advanced Studies in Seoul earlier this week, as reported by Bloomberg. Seo added that the company aims to initiate a new clinical trial to read speech from the brain, for which the U.S. Food and Drug Administration has granted it an Investigational Device Exemption.The exemption allows the company to start testing an unapproved device. Currently, there are no commercially available implants that read speech from the brain, Bloomberg noted. Neuralink is also working toward potential treatments for blindness and Parkinson’s disease, though it has yet to receive approval for any of its devices for commercial use.On Stocktwits, retail sentiment for <a href="https://stocktwits.com/symbol/NEURALINK">Neuralink</a> was ‘extremely bullish’ amid ‘extremely high’ message volume.Earlier this month, Neuralink <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-s-neuralink-expands-human-trials-as-12-patients-clock-15-000-hours-on-brain-chip/chwjH1mRdtC">announced</a> that 12 people worldwide are now living with its N1 implant, collectively recording more than 15,000 hours of device use across 2,000 days. The N1 is designed for people with quadriplegia caused by spinal cord injuries or Amyotrophic Lateral Sclerosis (ALS). Implanted through a surgical robot, the device enables users to move a computer cursor and interact with digital or physical tools solely through thought.According to Bloomberg, the company plans to implant devices in 20,000 people per year by 2031.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/equity/markets/kalvista-pharmaceuticals-hereditary-angioedema-drug-approved-in-eu-switzerland/chD3BkIR3TW">KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Neuralink logo is displayed on a mobile phone with Neuralink in the background in this photo illustration in Brussels, Belgium, on March 9, 2025. (Photo by Jonathan Raa/NurPhoto via Getty Images)

Elon Musk’s Neuralink Reportedly Plans To Translate Thoughts Into Text With Brain Implant Device

According to a Bloomberg report on Friday, Neuralink plans to launch a clinical trial in the U.S. in October for this purpose.

Equity

According to a Bloomberg report on Friday, Neuralink plans to launch a clinical trial in the U.S. in October for this purpose.


Neuralink, the brain-computer interface company founded by Elon Musk, said that 12 people around the world are now living with its N1 implant, collectively recording more than 15,000 hours of device use across 2,000 days.The update marks an expansion from June, when the company’s partner, the Barrow Neurological Institute in Phoenix, Arizona, announced that seven people with severe paralysis had received the device.&nbsp;At the time, Neuralink highlighted patients using the implant to play video games, design 3D machine parts, control robotic arms and communicate after losing speech due to amyotrophic lateral sclerosis (ALS).The N1 is designed for people with quadriplegia caused by spinal cord injuries or ALS. Implanted through a surgical robot, the device&nbsp;enables users to move a computer cursor and interact with digital or physical tools solely through thought.Neuralink also said in July that it is preparing to test its brain implant in Britain, partnering with University College London Hospitals and Newcastle Hospitals. Patients with severe paralysis will be eligible to enroll.The company raised $650 million in June to support its clinical studies. It began human trials in 2024 after addressing safety concerns raised earlier by the U.S. Food and Drug Administration, which initially rejected its application in 2022.On Stocktwits, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/NEURALINK">Neuralink</a> was ‘extremely bullish’ amid ‘low’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Elon Musk’s Neuralink Expands Human Trials As 12 Patients Clock 15,000 Hours On Brain Chip

The company also said in July that it is preparing to launch trials in Britain with top hospitals, expanding eligibility to patients with severe paralysis.

OpenAI and co-founder Sam Altman are reportedly set to back a startup that would compete with Elon Musk’s Neuralink.According to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/04484164-724e-4fc2-92a2-e2c13ea639bd?FTCamp&amp;#61;engage/">report</a> by the Financial Times, the company in question is Merge Labs. It is seeking funds at an $850 million valuation, with OpenAI’s ventures team expected to provide the bulk of the capital.&nbsp;While Altman will not be personally investing in the company, he will be one of the co-founders, the report stated. However, it added that he may not be involved in the new entity’s day-to-day operations.&nbsp;Insiders told the publication that Altman supports the investment. The report said that the OpenAI CEO plans to launch the project alongside Alex Bania, who runs World, a retina-scanning digital ID project, which Altman also backs.It noted that the new startup aims to build brain-computer interfaces, which would put it in direct competition against Musk’s Neuralink. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OPENAI">OpenAI</a> was in ‘extremely bullish’ territory, while retail sentiment around Musk’s <a href="https://stocktwits.com/symbol/NEURALINK">Neuralink</a> was in the ‘extremely bearish’ zone.The two billionaires have already&nbsp;<a href="https://stocktwits.com/news-articles/equity/markets/sam-altman-fires-back-at-elon-musk-over-apples-chatgpt-favoritism-claims/chrDUplRd7g">been at odds</a> of late, with Musk claiming on Monday that Apple (AAP) was biased toward OpenAI, making it “impossible” for other AI apps like xAI’s Grok to move up in the App Store’s rankings.&nbsp;"Apple is behaving in a manner that makes it impossible for any AI company besides OpenAI to reach #1 in the App Store, which is an unequivocal antitrust violation," Musk wrote on X. "XAI will take immediate legal action." xAI's Grok app currently sits in fifth position on the Apple App Store's top free apps chart, four spots away from ChatGPT. Retail sentiment on Stocktwits around <a href="https://stocktwits.com/symbol/XAI">xAI</a> was in 'bullish' territory at the time of writing.The pair co-founded OpenAI, though Musk exited the board in 2018 following disputes with Altman. The split sparked a bitter rivalry between the two as they fight for leadership in AI.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-tells-goldman-ceo-david-solomon-to-focus-on-being-a-dj/chrx4DMRdJg">Trump Tells Goldman CEO David Solomon To ‘Focus On Being a DJ’ Over ‘Bad’ Tariff Predictions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of 'OpenAI' is displayed on a mobile phone with the photographs of Elon Musk and Sam Altman in Ankara, Turkiye on March 14, 2024. (Photo by Muhammed Selim Korkutata/Anadolu via Getty Images)

Musk–Altman Battle Heats Up With OpenAI’s Reported $850M Bet On Neuralink Competitor

OpenAI’s ventures team is expected to contribute the bulk of the financing in Merge Labs’ $850 million valuation round, the Financial Times said.

NEURALINK
Neuralink Corp.

Latest NEURALINK News

NEURALINKNeuralink Corp.

Latest NEURALINK News

NEURALINK
Neuralink Corp.